Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Fibrosis and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for IL-11RA drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IL-11RA ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed for native glycosylation. |
View IL11RA Products |
| Gene Delivery | IL-11RA Promise-ORF / Lentivirus Full-length ORF for stable cell line development and cell-based signaling assays. |
View IL11RA Products |
| Benchmark Ab | Anti-IL-11RA (Sequence of BI 765128) Recombinant positive control antibody for functional validation. |
View IL11RA Products |
| Validator | IL-11RA siRNA Set For target knockdown and specificity verification in primary cells. |
View IL11RA Products |
| Related Target A | IL-11 The primary ligand. Essential for ligand-receptor binding assays and competitive blocking studies. |
View IL11 Products |
| Related Target B | GP130 (IL6ST) The signal transducing beta subunit. Crucial for assessing tripartite complex formation (IL-11/IL-11RA/GP130). |
View GP130 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation in preclinical fibrosis models | Human, Mouse, and Cynomolgus ortholog proteins available with >95% purity verified by SDS-PAGE. |
| Selectivity screening against related IL-6R subfamily receptors | Homolog panel proteins (IL-6R, CNTFR) strictly verified by mass spectrometry to eliminate off-target risks. |
| Lack of reliable positive controls for functional assays | Clinical Benchmark Antibodies (Biosimilars) sequence-verified and produced recombinantly in-house. |
| False positives in high-throughput ligand-blocking screens | Validated siRNA sets included for target-specific knockdown verification in target cells. |
Live IL-11RA R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IL-11RA therapeutics is intensifying, with major players shifting focus from traditional systemic cytokine inhibitors to highly localized, tissue-specific blockades. As first-generation therapies targeting the IL-11 pathway reach the clinic, the next wave of R&D is targeting the specific blockade of the alpha receptor (IL-11RA) to prevent both cis- and trans-signaling pathways that drive fibro-inflammatory diseases.
Targeting IL-11RA offers a distinct therapeutic advantage over targeting the ligand (IL-11) itself, as it directly shuts down the receptor complex assembly on myofibroblasts and tumor-associated fibroblasts, avoiding the potential sink effect of high systemic ligand concentrations. The pipeline is currently dominated by monoclonal antibodies and novel scaffold proteins aiming to resolve chronic fibrotic indications such as Idiopathic Pulmonary Fibrosis (IPF), Non-Alcoholic Steatohepatitis (NASH), and diabetic nephropathy.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | Boehringer Ingelheim, Enleofen | IPF, NASH, Renal Fibrosis | Receptor blocking & cross-species binding assays (Need high-purity Human/Mouse/Cyno ECD-Fc) |
| Lasso Peptide / Novel Scaffolds | Lassogen | Inflammatory Bowel Disease (IBD), Fibrosis | High-affinity screening and structural stability assays (Need sequence-verified, endotoxin-controlled proteins) |
| Bispecific Antibodies | Oncology-focused Biotechs | Solid Tumors (TME modulation) | Simultaneous binding kinetics and GP130 recruitment assays (Need GP130 and IL-11RA co-validation panels) |